非受体酪氨酸激酶在乳腺癌组织的表达及其与预后的关系

Expression of Src in breast cancer and its relationship with prognosis

目的探讨非受体酪氨酸激酶Src与乳腺癌临床病理特征及预后的关系。方法262例乳腺浸润性导管癌患者，采用组织芯片免疫组织化学法分析Src的表达，分析Src表达与乳腺癌临床病理特征的关系，并进行生存分析探讨其预后价值。结果262例乳腺癌组织中Src阳性表达率为47．3％。Src阳性表达与淋巴结转移及Her-2表达明显相关（P〈O．05）。Src阳性患者的总生存期（OS）低于Src阴性患者（P〈0．05）。淋巴结阴性患者中，Src阳性患者与Src阴性患者比较OS明显缩短（P〈0．01）。Luminal A型患者中，Src阳性患者的OS明显降低（P〈0．05）。Cox多因素分析显示Src阳性为乳腺癌不良预后的独立预测指标。结论SIc阳性表达预示着乳腺癌的不良预后；淋巴结转移阴性／Src阳性和Luminal A型／Src阳性的患者，早期使用Src抑制剂可能改善其预后。

Objective To explore Src expression and its effects on the prognosis of breast cancer. Methods We used immunohistochemistry to detect the Src expression in 262 cases of invasive breast cancer by tissue microarrays. The correlation between Src expression and clinicopathologic features were analyzed. Survival analysis and the Cox proportional hazards model were used to explore the prognostic value of Src expression in breast cancer. Results The Src expression rate in 262 cases of breast cancer was 47.3%. Src expression was significantly associated with lymph node metastasis and Her- 2 expression （P 〈 0. 05 for both）. The patients who exhibited Src expression demonstrated poor overall survival （OS） （ P 〈 0. 05）. Subgroup analysis demonstrated that lymph node metastasis negative/Src positive patients and Luminal A/Src positive patients exhibited significantly worse OS （P 〈 0.05, respectively）. Multivariate analysis demonstrated that Src expression was an independent predictor of OS for patients with breast cancer. Conclusion Src expression predicts a poor prognosis in patients with breast cancer. For lymph node metastasis negative/Src positive patients and Luminal A/Src positive patients, Src inhibition therapy may be necessary to improve the poor prognosis.